Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
Recruiting · NCT06249750 · Interventional (participants receive a specific treatment) · Lead sponsor: Pengyuan Liu
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
Who can take part
Age range
18 Years to 90 Years
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC;
- Complete and reliable medical history and medical records;
- No other primary tumors except CRPC;
- Blood tests, liver function, renal function and electrocardiogram are basically normal;
- Patients with ECOG score 0\~3, aged ≥18 years and \<90 years old;
- Patients with good compliance, able to accept regular follow-up.
Exclusion criteria
- History of malignant tumor other than PC within the past 5 years;
- Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study;
- Accompanied by severe underlying diseases that cannot tolerate this therapy;
- With acute diseases, such as acute infection, active bleeding;
- Those who have recently participated in other clinical trials and have not passed the washout period;
- Those who cannot tolerate systemic heat stress, such as claustrophobic patients;
- Those who have a history of allergy to the drugs used in the trial;
- Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.
Where it is running
1 location listed.
- Zhejiang Hospital - Hangzhou, Zhejiang, China